Bank of America’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Bank of America’s Portfolio DRMAW Stock Details DRMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100	Closed	-$1	–	8363
2024 Q4	$1	Hold	100	–	–	﹤0.01%	8146
2024 Q3	$1	Sell	100 -100	-50%	-$1	﹤0.01%	8130
2024 Q2	$3	Buy	200 +100	+100%	+$1	﹤0.01%	8145
2024 Q1	$1	Buy	+100	New	+$2	﹤0.01%	7650
2023 Q2	–	Sell	-100	Closed	-$2	–	7755
2023 Q1	$2	Hold	100	–	–	﹤0.01%	7713
2022 Q4	$1	Buy	+100	New	+$3	﹤0.01%	8175

Other funds holding DRMAW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America's DRMAW Position: Q1 2025 in Review

Bank of America sold out of Dermata Therapeutics Warrant (DRMAW) in Q1 2025, closing a stake of 100 shares — an estimated $1 sold.

Bank of America first reported a position in DRMAW in Q4 2022 and held it in 6 quarters. The position peaked at $3 in Q2 2024. 3 funds tracked by Wall St. Rank hold DRMAW as of Q1 2025.

Bank of America reported no remaining Dermata Therapeutics Warrant position as of Q1 2025 after selling out during the quarter.
Bank of America sold 100 Dermata Therapeutics Warrant shares in Q1 2025, an estimated $1.
Bank of America first reported a position in Dermata Therapeutics Warrant in Q4 2022 and held it in 6 quarters.
Bank of America's Dermata Therapeutics Warrant position peaked at $3 in Q2 2024.
3 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q1 2025.

Based on Bank of America's 13F filing for Q1 2025, filed 15 May 2025.